IL22

Across TCGA pan-cancer cohorts, IL22 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IL22 data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IL22 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IL22 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and GBM are the cancer types where IL22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.954	0.623	<.001	31	view →
LUAD	DFS	Tertile	III,IV	0.935	0.257	.006	17	view →
GBM	DFS	Median	All	0.637	0.848	.023	8	view →
PDAC	OS	Tertile	All	0.686	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IL22–HNSC (DFS)

Open the HNSC breakdown →